We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byMegan Adams
Modified over 3 years ago
Cardiovascular effects of anti-hyperglycemic therapy Edoardo Mannucci Diabetes Agency Careggi teaching hospital, Firenze, Italy
MACE CV mort.
Effects of intensified glycemic control on CV mortality
MYOCARDIAL ISCHEMIA Adrenercic activation could have a negative impact on the prognosis of
Secondary prevention of macrovascular events in patients with type 2 diabetes: The PROACTIVE Study Dormandy JA et al., Lancet 2005; 366: 1279
Relative risk SU vs other therapies vs. Conventional vs. Insulin vs. Metformin Mortality0.961.031.53 MI0.830.911.24 Stroke1.191.402.12
Effect of SU on MACE Monami M, Ganovese S, Mannucci E – 2013 [in press]
Effect of SU on mortality Monami M, Ganovese S, Mannucci E – 2013 [in press]
An initiative of South Asian Federation of Endocrine Societies (SAFES)
PPAR activation Clinical evidence. Evolution of clinical evidence supporting PPAR activation and beyond Surrogate outcomes studies Large.
VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%) <
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Glycemic Control: When the Lower is Not the “Better”?
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Vascular effects of PPAR activation: Inflammation.
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Demystifying Cardiovascular Safety of Sulfonylurea.
1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.
Prevalence (%) estimates of diabetes (20-79 years) 2010.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:
© 2017 SlidePlayer.com Inc. All rights reserved.